0HNZ.L - Fagron NV
| Chiusura precedente | 14,87 |
| Aperto | 14,91 |
| Denaro | N/D x N/D |
| Lettera | N/D x N/D |
| Min-Max giorno | 14,84 - 15,01 |
| Intervallo di 52 settimane | 14,84 - 15,01 |
| Volume | |
| Media Volume | N/D |
| Capitalizzazione | N/D |
| Beta (5 anni mensile) | 0,45 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | N/D |
| Prossima data utili | N/D |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireFagron shareholders approve majority voting items
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 8 May 2023 – 7 PM CET Fagron shareholders approve majority voting items Today, Fagron, the leading global player in pharmaceutical compounding, held its annual general meeting of shareholders. The meeting approved the voting items, with the exemption of the proposal to approve the accelerated vesting in case of a public offer on or a change of control over Fagron as provided for in the Performance Share Plan (agenda item 10). T
- GlobeNewswire
Fagron increases share capital through exercise subscription rights
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 3 May 2023 – 8:00 AM CET Fagron increases share capital through exercise subscription rights Fagron, the leading global player in pharmaceutical compounding, announces that as a result of the exercise of subscription rights, 236,250 new shares have been issued on 2 May 2023. These newly issued shares are entitled to dividend as of financial year 2022. In accordance with the Belgian transparency legislation, Fagron notes that it
- GlobeNewswire
Strong first quarter performance with 16% topline growth to €181 million
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 13 April 2023 – 7:00 AM CET Strong first quarter performance with 16% topline growth to €181 million Fagron, the leading global player in pharmaceutical compounding today publishes its quarterly results for the period ending 31 March 2023. Key Highlights Q1 2023 topline and organic growth across all regions Revenue increased by 16.0% to €181.4 million (12.8% at CER) driven by organic growth, acquisitions, and FXOrganic revenue
- GlobeNewswire
Fagron publishes agenda for annual shareholders meeting
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 7 April 2023 – 8AM CET Fagron publishes agenda for annual shareholders meeting The Board of Directors of Fagron NV invites shareholders and other persons authorized to attend general meetings to attend Fagron’s annual general meeting of shareholders on Monday 8 May 2023. AgendaThe agenda includes the discussion of the annual report, the approval of the annual financial statements and the dividend proposal of €0.25 for the fisca
- GlobeNewswire
Disclosure of notification received from FMR LLC
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 20 March 2023 – 6:30 PM CET Disclosure of notification received from FMR LLC Fagron received a notification pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies from FMR LLC. Notification of FMR LLC On 16 March 2023, Fagron received a notification that the shareholding of FMR LLC crossed the disclosure threshold of 5% on 15 March 2023 as the result of the disposal of voti
- GlobeNewswire
Fagron publishes annual report 2022
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 20 March 2023 – 8:00 AM CET Fagron publishes annual report 2022 Fagron, the leading global player in pharmaceutical compounding, today publishes its annual report 2022. Discussion of the annual report and the approval of the financial statements will be put on the agenda of the annual general meeting of shareholders early May. The annual report is available in the official Dutch version and in English translation on Fagron’s we
- GlobeNewswire
Fagron reports 19% topline growth, 11% increase in REBITDA and free cash flow of €91 million for 2022
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 9 February 2023 – 7.00 AM CET Fagron reports 19% topline growth, 11% increase in REBITDA and free cash flow of €91 million for 2022 Fagron, the leading global player in pharmaceutical compounding today publishes its full year results for the period ending 31 December 2022. FY 2022 Key Highlights Revenue growth of 10.3% at CER with organic revenue growth of 3.8% at CER to €683.9 million (€676.7 million excluding Boston)REBITDA i
- GlobeNewswire
Disclosure of notifications received from Active Ownership Corporation S.à r.l. and from AOC Pharma S.à r.l.
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 19 December 2022 – 7:30AM CET Disclosure of notifications received from Active Ownership Corporation S.à r.l. and from AOC Pharma S.à r.l. Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Fagron received notifications from Active Ownership Corporation S.à r.l. and AOC Pharma S.à r.l. Notification Active Ownership Corporation S.à r.l. On 15 December 2022, Fagron recei
- GlobeNewswire
Disclosure of notification received from Active Ownership Corporation S.à r.l.
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 28 October 2022 – 6PM CET Disclosure of notification received from Active Ownership Corporation S.à r.l. Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Fagron received a notification from Active Ownership Corporation S.à r.l. Notification Active Ownership Corporation S.à r.l. On 27 October 2022, Fagron received a notification that the shareholding of Active Ownersh
- GlobeNewswire
Fagron delivers topline growth of 21.5% to €173 million
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 13 October 2022 – 7.00 AM CET Fagron delivers topline growth of 21.5% to €173 million Fagron, the leading global player in pharmaceutical compounding today publishes its quarterly results for the period ending 30 September 2022. Key Highlights Q3 2022 topline growth across all regions Revenue increased by 21.5% to €173 million (10.7% at CER) driven by organic growth, acquisitions, and FXOrganic revenue growth of 11.5% for Q3 20
- GlobeNewswire
Fagron commits to set science-based emission reduction targets
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 27 September 2022 – 8 AM CET Fagron commits to set science-based emission reduction targets Fagron, the leading global player in pharmaceutical compounding, announces that it has committed to set science-based emission reduction targets and have these validated by the Science Based Targets initiative (SBTi) to meet the goals of the Paris Agreement of limiting global warming to 1.5°C. Rafael Padilla, CEO of Fagron commented“By c
- GlobeNewswire
Disclosure of notification received from Templeton Investment Counsel, LLC
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 20 September 2022 – 7:00 PM CET Disclosure of notification received from Templeton Investment Counsel, LLC Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Fagron received a notification from Templeton Investment Counsel, LLC. Notification Templeton Investment Counsel, LLC On 14 September 2022, Fagron received a notification that the shareholding of Templeton Investm
- GlobeNewswire
Disclosure of received notification of Kabouter Management LLC
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 2 September 2022 – 6:00 PM CET Disclosure of received notification of Kabouter Management LLC Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Fagron received a notification from Kabouter Management LLC. Notification of Kabouter Management LLC On 1 September 2022, Fagron received a notification that the shareholding of Kabouter Management LLC had crossed the lowest d
- GlobeNewswire
Disclosure of received notification from The Goldman Sachs Group, Inc. and NN Group N.V.
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 26 August 2022 – 8AM CET Disclosure of received notification from The Goldman Sachs Group, Inc. and NN Group N.V. Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies (the Law), Fagron received notifications from The Goldman Sachs Group, Inc. and NN Group N.V. Notification from The Goldman Sachs Group, Inc. On 23 August 2022, Fagron received a notification that the shareh
- GlobeNewswire
Fagron delivers strong topline growth of 18.8% and an increase in REBITDA of 13.1% for the first half of 2022
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 4 August 2022 – 7.00 AM CET Fagron delivers strong topline growth of 18.8% and an increase in REBITDA of 13.1% for the first half of 2022 Fagron, the leading global player in pharmaceutical compounding today publishes its half year results for the period ending 30 June 2022. Key Highlights Organic revenue growth of 6.9% at CER with total revenue growth of 10.9% at CER (18.8% reported) to €328.6 millionRevenue development in EME
- GlobeNewswire
Fagron expands its US sterile compounding footprint with East coast acquisition
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 5 July 2022 – 7AM CET Fagron expands its US sterile compounding footprint with East coast acquisition Fagron, the leading global player in pharmaceutical compounding, has acquired from Fresenius Kabi a 503B outsourcing facility in Boston. The transaction covers all operational aspects of the facility, including customers, suppliers, and around 80 employees, as well as a supply agreement with Fresenius Kabi. Rafael Padilla, CEO